Skip to main content
  • Home
  • About
  • Faculty Experts
  • For The Media
  • ’Cuse Conversations Podcast
  • Topics
    • Alumni
    • Events
    • Faculty
    • Students
    • All Topics
  • Contact
  • Submit
Syracuse University Impact
  • All News
  • Arts & Culture
  • Business & Economy
  • Campus & Community
  • Health & Society
  • Media, Law & Policy
  • STEM
  • Veterans
  • University Statements
  • Syracuse University Impact
  • |
  • The Peel
  • Athletics
Sections
  • All News
  • Arts & Culture
  • Business & Economy
  • Campus & Community
  • Health & Society
  • Media, Law & Policy
  • STEM
  • Veterans
  • University Statements
  • Syracuse University Impact
  • |
  • The Peel
  • Athletics
  • Home
  • About
  • Faculty Experts
  • For The Media
  • ’Cuse Conversations Podcast
  • Topics
    • Alumni
    • Events
    • Faculty
    • Students
    • All Topics
  • Contact
  • Submit
Syracuse University Impact

Striving to Improve the Efficacy of Obesity, Diabetes Treatments (Podcast)

Wednesday, March 26, 2025, By John Boccacino
Share
'Cuse Conversations PodcastCollege of Arts and SciencesfacultyresearchResearch and CreativeSTEM Transformationstudent researchSyracuse University Impact

The image is a promotional graphic for a podcast episode titled "'Cuse Conversations." It features episode number 175 and highlights Robert Doyle, who is identified as the Jack and Laura H. Milton Professor of Chemistry. The image includes a blurred-out photo of a person on the left side, with a microphone icon above it. The background is blue with orange and white text, and there is an orange "S" logo in the top right corner.

The cutting-edge weight loss and diabetes research developed by medicinal chemist Robert Doyle has offered significant and consistent weight loss and glucose control to its recipients through peptide-based treatments.

Doyle and his fellow collaborators reported that two new peptide compounds­­—GEP44 and KCEM1—considerably reduce body weight and normalize blood glucose levels without causing the typical negative side effects experienced by patients who take currently available GLP-1-based anti-obesity drugs.

Doyle, the Jack and Laura H. Milton Professor and Dean’s Professor of Chemistry in the College of Arts and Sciences, focuses his research on pharmaceutical drug development for the treatment of obesity and type 2 diabetes. He says that while the first-generation of weight-loss drugs did lead to results, there was a problem: while weight loss occurred, it was almost a reaction to taking the GLP-1 peptide, and that weight loss came with a cost.

Due to side effects like nausea, vomiting, diarrhea and abdominal pain, 70% of patients who started taking these drugs were not taking them one year later, and that 30% stopped taking the drugs within three months, generating a very low patient tolerability for the drugs, Doyle says.

A person poses for a headshot.

Robert Doyle

The recent discoveries Doyle and his collaborators introduced at conferences of the American Chemical Society and The Obesity Society give hope for those battling obesity and type 2 diabetes. The methodology behind these peptide and similar weight-loss compounds could also hold the key to treating two other public health crises: cardiovascular disease, the leading cause of death in the U.S., and opioid addiction.

“As medicinal chemists, we are focused on using peptides, or small proteins, to treat neuroendocrine disorders, primarily disorders that affect the brain,” says Doyle, the Dean’s Professor of Chemistry and adjunct associate professor of medicine and pharmacology. “We are looking at addiction, cravings, food intake, body weight reduction, glucose regulation, all those complex endocrine issues that are prevalent today.”

On this “’Cuse Conversation,” Doyle discusses his breakthrough weight loss research, the important role students play in advancing his research, and how, through philanthropy, his work has come to life.

Check out episode 175 of the “’Cuse Conversations” podcast featuring Doyle. A transcript [PDF] is also available.

How has this field evolved over the years?

The image shows a gloved hand holding a small vial containing a yellow liquid with handwritten labels. In the foreground, there are two other vials with similar yellow liquids and handwritten labels. In the background, there is a 300 ml beaker with printed text: "300 ml FLASK NO. T-25000 PART OF ASSY NO. 745000." The setting appears to be a laboratory with various equipment and supplies visible in the background.

A team of researchers at Syracuse University, led by medicinal chemist Robert Doyle, has co-developed a novel treatment for obesity and type 2 diabetes without any of the harmful side effects.

The major change in the last 10 years is the creation of these GLP-1 drugs, exemplified by Ozempic and Zepbound. Until these drugs existed, there were no safe, viable weight loss alternatives. Diet and exercise have always been on the table, of course, but for people who needed or wanted a pharmaceutical intervention, there was nothing that could achieve anything greater than the 5% body mass index [BMI] loss that you’d be looking for to have any kind of clinical benefit.

With the creation of the first real breakthrough drug, Victoza, you were seeing that 5% BMI decline from a pharmaceutical perspective, and that was a huge success. That set the stage for these newer, more potent and more active weight-reducing drugs. But those initial drugs were often once- or twice-a-day injectables, and patients didn’t want to do that. In these last few years, we have upwards of 10% and greater body mass reduction coupled with once-a-week injectables. That has really broadened the appeal and created quite a phenomenon.

How did we proceed from the first generation of weight loss drugs to where we are now?

There was this discovery that this little hormone that you make in your stomach, if made long-acting and then injected, could trigger food intake reduction. We realized that and did pharmacological science to improve its half-life, make it hang around longer so it would maintain what was normally only a very short activity in a human. We drove that appetite off switch. The discovery of GLP-1—and what GLP-1 could do—hasn’t won a Nobel Prize yet, but it is going to. I wouldn’t be surprised this year if you see the Nobel Prize awarded for the discovery of GLP-1 because it has revolutionized weight loss.

How has Syracuse’s Center for Science and Technology enhanced your studies?

The image shows four individuals wearing blue lab coats standing in a laboratory. One person is holding a small yellow object, while another person points at it. There are various laboratory equipment and supplies visible in the background, including shelves and containers.

Robert Doyle works alongside student researchers. (Photo by Evan Jenkins)

Within my own lab, we have multiple large scale peptide synthesizers that allow us to produce gram quantities of these drugs. We have multiple purification setup systems so that we’re able to purify to 99%, and we have cell labs that can screen for the required receptor binding.

We also have artificial intelligence and a molecular operating environment, these computational chemical approaches to aid in design. We can start from a concept on a piece of paper, begin to design something computationally and then physically make it in the lab. If it makes the grade, we put something in place that outlines what we want the drug to be able to do, and if it meets those criteria, it goes out into preclinical animal models at the University of Pennsylvania in this case. We’ll look and see if what we’ve created here is manifesting the effect we want it to in that preclinical model. If not, we go back to the drawing board. But if it does, we call that a hit and we’ll begin the process of optimizing it for development.

How do our students assist with your research?

They’re the ones who are in there grinding out the production, the purification, the screening, the failures and the redesigning. They bring passion and intellect. They’re wonderful. They roll up their sleeves. They jump wholeheartedly into all the aspects of drug development. I have to be willing to trust them that they’ll do it right. They have that sense of confidence, inquisitiveness and can-do. Every day they surprise me with some wonderful question or clever idea.

The image shows two people in blue lab coats standing in a laboratory. The person on the left is gesturing with one hand while talking to the other person. The laboratory is equipped with various scientific instruments, including a large machine with multiple compartments and shelves filled with bottles and containers.

Robert Doyle talks with lab member Emily Ashlaw G’27, a Ph.D. candidate interested in peptide therapeutics.

  • Author

John Boccacino

  • Recent
  • Chancellor Kent Syverud Honored as Distinguished Citizen of the Year at 57th Annual ScoutPower Event
    Thursday, May 8, 2025, By News Staff
  • New Maymester Program Allows Student-Athletes to Develop ‘Democracy Playbook’
    Thursday, May 8, 2025, By Wendy S. Loughlin
  • From Policy to Practice: How AI is Shaping the Future of Education
    Thursday, May 8, 2025, By Christopher Munoz
  • Kohn, Wiklund, Wilmoth Named Distinguished Professors
    Thursday, May 8, 2025, By Wendy S. Loughlin
  • Major League Soccer’s Meteoric Rise: From Underdog to Global Contender
    Wednesday, May 7, 2025, By Keith Kobland

More In Syracuse University Impact

Serving Those Who Served: The Betty and Michael D. Wohl Veterans Legal Clinic

Service members injured in active duty are entitled to receive disability benefits and associated medical care from the U.S. Department of Veterans Affairs (VA). But navigating the process can be intimidating. Thanks to the efforts of the Betty and Michael…

Innovative Student Group Designs Inclusive Clothing for Neurodivergent Community

Carolyn Fernandes ’25 remembers walking out of an interview for a design internship that she ended up not getting. She wondered if fidgeting with her nails—a common, repetitive expression of her nervous energy every day—was misconstrued as a sign of…

Celebrating 30 Years of the Shaw Center as a Hub for Academic Community Engagement (Podcast)

Community engagement. Reciprocal learning. Service to others through volunteering. Those were the principles behind the creation of the Mary Ann Shaw Center for Public and Community Service in 1994 under the direction of then-Syracuse University Chancellor Kenneth Shaw and his…

Students Helping Children’s Hospital Patients Through Play Sessions

Jonida Konjufca was not sure what she wanted to do professionally before she enrolled in the Department of Human Development and Family Science (HDFS), but her professors and coursework soon opened her eyes. “I couldn’t imagine myself anywhere else. HDFS…

University Community, Sleep in Heavenly Peace Build 88 Beds for Local Children

Last year, the Syracuse University Volunteer Organization (SUVO) took on its first bed build event on campus. The organization teamed up with the local chapter of Sleep in Heavenly Peace (SHP) to build 44 beds for children in the community….

Subscribe to SU Today

If you need help with your subscription, contact sunews@syr.edu.

Connect With Us

  • X
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
Social Media Directory

For the Media

Find an Expert Follow @SyracuseUNews
  • Facebook
  • Instagram
  • Youtube
  • LinkedIn
  • @SyracuseU
  • @SyracuseUNews
  • Social Media Directory
  • Accessibility
  • Privacy
  • Campus Status
  • Syracuse.edu
© 2025 Syracuse University News. All Rights Reserved.